RecruitingNot ApplicableNCT06405776

Effect of Lidocaine on Postoperative Pain and Long-term Survival in Elderly Patients Undergoing Colorectal Surgery

Effect of Perioperative Continuous Intravenous Infusion of Lidocaine on Postoperative Pain and Long-term Survival in Elderly Patients Undergoing Colorectal Cancer Surgery: a Prospective, Randomized Controlled Trial


Sponsor

West China Hospital

Enrollment

276 participants

Start Date

Jun 5, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a further observation and follow-up of the patients enrolled in the registration number NCT05920980 to further evaluate the effect of long-term infusion of lidocaine on postoperative chronic pain, long-term quality of life and survival rate in patients undergoing colorectal cancer surgery.


Eligibility

Min Age: 60 Years

Inclusion Criteria4

  • Participants were at least 60 years old;
  • American Society of Anesthesiologists (ASA) physical status I to III;
  • Body-mass index of 18-30 kg/m2;
  • Scheduled for elective colorectal surgery.

Exclusion Criteria6

  • Metastases occurring in other distant organs;
  • Severe hepatic insufficiency (aspartate aminotransferase or alaninetransaminase or bilirubin \>2.5 times the upper limit of normal);
  • Renal impairment (creatinine clearance \<60 mL/min);
  • Cardiac rhythm disorders or systolic heart failure (second-and thirddegree heart block, ejection fraction \<50%);
  • Allergies to any of the trial drugs; chronic opioid use;
  • Inability to comprehend numeric rating scale.

Interventions

DRUGlidocaine

Patients in the lidocaine group, lidocaine 1.5mg/kg/h is continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg) diluted to 200ml with saline until 72h after surgery.

DRUGPlacebo

In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.


Locations(1)

China

Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06405776


Related Trials